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Pregnancy in patients suffering from undifferentiated connective tissue disease 
(UCTD) represents a risk situation for both the mother and the child. SSA/SSB 
autoantibodies can determine neonatal lupus (NL) in the foetus, regardless of the 
maternal disease. Furthermore, pregnancy increases the risk of flares and 
evolution to differentiated connective tissue disease (CTD).We report an 
uncommon case in which these complications occurred in a mother and in her 
foetuses. A 37-year-old woman affected by UCTD developed systemic lupus 
erythematosus (SLE) after her triplet pregnancy. 
The only manifestation of neonatal lupus we observed in the three newborns 
was SSA positivity associated with asymptomatic transient neutropenia.  
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INTRODUCTION   
Currently, the number of women affected by connective tissue diseases (CTDs) 
who decide to have children has increased thanks to the diagnostic 
improvements and to the multidisciplinary management of the patient. 
Pregnancies that are planned during the inactive phase of the disease do not 
usually result in any detrimental effects.1 Patients who are affected by 
undifferentiated connective tissue diseases (UCTDs), which are usually 
benign,2,3 generally have no absolute contraindications for pregnancy.4 
However, pregnancy in CTD patients still represents a risk situation for both the 
mother and the child. It is well known that maternal anti-Ro/SSA and/or anti-
La/SSB autoantibodies can cross through the placenta causing possible damage 
to the foetus, likely leading to neonatal lupus syndrome (NL), regardless of the 
maternal disease. The most severe manifestation of NL is congenital complete 
heart block (CHB), resulting in a permanent change in the heart conduction 
tissue due to inflammation and fibrosis of the conducting system.5 NL may also 
be characterised by photosensitive rash, haematological abnormalities or liver 
dysfunction, all of which resolve at approximately 6 months of life when 
maternal antibodies disappear from the neonatal circulation. On the contrary, 
CHB results in significant mortality (15–30%) and morbidity in the newborn. As 
a matter of fact, 67% of the surviving affected children require permanent 
pacing.5 We report the case of a 37-year-old woman suffering from UCTD who 
developed SLE after her triplet pregnancy and whose newborns were diagnosed 
with neonatal lupus.   
Case report  
A 37-year-old woman came to our attention during the 8th week of a trichorionic, 
triamniotic triplet invitro fertilisation (IVF) pregnancy. She underwent IVF because of 
tubal factor infertility caused by right salpingectomy and left hydrosalpinx that were 
the result of a previous pelvic Chlamydia infection. Her 10-year medical history 
included alopecia (successfully treated with prednisone), associated with positivity for 
antinuclear antibodies (ANA), 1:320 titre with a speckled pattern (indirect 
immunofluorescence in HEp-2), anti-Ro/SSA (ELISA), Lupus Anticoagulant (Stago 
Roche for APTT, LAC screen IL for DRVVT, home-made KCT), anticardiolipin 
(aCL) and anti-β2GPI, twice confirmed high titre in ELISA, and VDRL false 
positivity. Serum C3 and C4 levels were 70 mg/dL (normal 76–171) and 12 mg/dL 
(normal 10–40), respectively. When she came to our attention, the patient reported 
photosensitive rash, fatigue, Raynaud’s phenomenon and recurrent urinary tract 
infection (UTI). The patient did not have a history of recurrentmiscarriage, 
thrombosis, joint pain and arthritis, oral aphthosis, xerophthalmia or xerostomia. 
Recent laboratory tests showed positivity for ANA, SSA, aCL and anti-β2GPI (both 
IgG low title) and negativity for anti-DNA and LA. Homocysteine, antithrombin III, 
C and S proteins, serum C3 and C4, complete blood count and hepato-renal function 
were all normal. Clinical and laboratory data supported a diagnosis of UCTD 
according to Mosca’s criteria.2 We confirmed her current therapy: 
hydroxychloroquine (HCQ), folic acid, low-dose aspirin (LDA) and we continued 
anti-coagulation prophylaxis with low– molecular weight heparin (LMWH), which 
had been started during IVF. During pregnancy, she gained 12 kg, her blood pressure 
was normal, and there were no signs/ symptoms of flare. Recurrent bacterial UTI 
occurred. Amniocentesis was performed at the 17th week. No abnormalities were 
observed, and results showed one male and two female foetuses. Foetal 
echocardiograms were performed at the 21st, 24th, 27th and 30th week of pregnancy 
and were normal. Doppler flowmetre evaluations at the 21st and 30th week were 
normal as well. Foetal morphologic ultrasound (US) studies performed at the 21st 
week showed renal pelvis dilatation in the male foetus. A caesarean section was 
performed at the 33rd week of pregnancy following the premature rupture of 
membranes (PROM). The male newborn (triplet 1) weighed 2200 g and the two 
females (triplets 2 and 3) weighed 1900 g and 1550 g, respectively. Triplets 1 and 3 
showed mild respiratory distress that was treated with oxygen for the first 3 days of 
life. The babies were placed in incubators for the 1st week of life. Abdominal US 
study of triplet 1 confirmed mild bilateral pyelectasis and no ultrasound findings of 
vesicoureteral reflux. The newborn was treated with antibiotic prophylaxis and was 
discharged from hospital when he was 13 days old. The three newborns showed SSA 
positivity associated with asymptomatic transient neutropenia and negative anti-
neutrophil antibodies. Figure 1 shows the neutrophil count in the newborns. 
Neutrophil leukocyte levels normalised following antibody seroconversion, which 
occurred when the babies were 50 days old. The newborns underwent ECG, and no 
abnormalities were found. Currently, the 3-year-old children show regular growth, 
and no symptoms and/or signs of any neurological pathologies have been observed. 
During the post-partum period, the mother remained asymptomatic and she continued 
LMWH prophylaxis for 8 weeks after which LDA administration was started again. 
Six months later, while on therapy with LDA 100 mg and HCQ 200 mg, the patient 
reported oral aphtosis and joint pain; diffuse erythema of the face with a butterfly 
configuration appeared. Because clinical findings were not specific, a biopsy was 
performed, which showed a histologic pattern that was suggestive of discoid lupus. 
She was successfully treated by increasing the dose of HCQ to 400 mg associated 
with topical corticosteroids and photoprotection.  
Discussion  
Two types of immunological disease related problems may develop during pregnancy 
in CTD patients.7 One refers to the mother’s risk of developing CTD flares and/or 
thrombotic events, whereas the other is linked to the risk of miscarriage, intrauterine 
growth restriction (IUGR) and neonatal lupus. We report an uncommon case in which 
both these immunological disease related problems occurred. However, it must be 
kept in mind that triplet pregnancy itself already represents a higher risk situation. 
Recently, important progress in the characterisation of autoantibodies and in the 
immunogenetics of CTD have increased our understanding of these diseases. 
Nonetheless, classification of many rheumatic diseases remains unclear.2 Upon her 
first admission to our hospital, the patient showed an undifferentiated pattern 
(photosensitivity, alopecia, Raynaud’s phenomenon) with LA and ANA, SSA, aCL 
autoantibodies and with false positive VDRL. She had been treated at another centre 
with HCQ and LDA therapy. It is well known that the end of pregnancy can interfere 
with the clinical course of systemic autoimmune diseases7; Mosca, et al.8 actually 
assumed that pregnancy could represent a trigger causing UCTD to evolve to a 
definite CTD. In our case, UCTD evolved to systemic lupus erythematosus with 
articular, mucosal and skin involvement (discoid rash, oral aphtosis). The term 
“undifferentiated connective tissue disease” is used for conditions that are 
characterised by the presence of signs and symptoms suggestive of a systemic 
autoimmune disease, but that do not fulfil the classification criteria of any defined 
CTD, such as SLE, Sjogren syndrome, rheumatoid arthritis.2 The term UCTD 
involves a heterogeneous group of diseases that are likely to remain unmodified over 
time, to evolve to otherwise classifiable diseases or to regress spontaneously.3 
UCTDs intrinsically present classification and prognostic problems due to the 
overlapping clinical and laboratory features and to the lack of definitive 
characteristics at onset. Doria, et al. suggested that various populations may exist 
within the group of patients with unclassifiable CTDs: patients with incomplete SLE 
are the ones who will develop definite SLE, and therefore incomplete SLE could be 
considered an early stage of SLE, whereas UCTDs represent truly undifferentiated 
conditions that could potentially evolve into different types of CTDs.3 About 25% of 
patients with an undifferentiated disease at onset will evolve to defined CTD during 
follow-up.2 This evolution usually occurs within the first 5 years, and most often 
involves SLE. The factors that predict the shift from UCTD to defined CTD have 
been identified. The presence of anti-dsDNA, anti-Sm and anti-phospholipid 
antibodies, as well as serositis, alopecia, photosensitivity and discoid rash are 
predictive of evolution to SLE. To date, no triggering factors that might account for 
the progression to defined CTDs have been identified. Therefore, it is important to 
follow up patients closely, especially at disease onset and in conditions such as 
pregnancy when the risk of flare seems to be higher.9 Our patient showed false 
positive VDRL, aCL high titre IgG, anti-β2GPI and LA positivity, which are 
laboratory criteria suggestive of the antiphospholipid syndrome (APS). Throughout 
gestation, we continued treating her with LMWHanticoagulation prophylaxis (which 
had been started during IVF) and with LDA. Despite the international APS 
recommendations, we decided to administer this combined treatment for several 
reasons, including high thrombotic risk during triplet pregnancy, advanced age, and 
positive anamnesis for infertility.10 SSA and/or SSB positive patients may develop 
diffuse exocrinopathy involving the mucosal lining of the upper airways and the 
vagina, thus increasing their predisposition to local infections.Our patient reported 
suffering from recurrent UTIs for several years, and during pregnancy, she had 
recurrent bacterial cystitis. We think that in her case, PROM may have been related to 
urinary tract and vaginal infections and to the triplet pregnancy.11 With regards to 
NL, the only manifestation we observed in all three newborns was asymptomatic 
neutropenia, which disappeared when the maternal SSA antibodies cleared from the 
babies’ circulation. As is the case with twins, NL manifestations in triplets can also be 
discordant (Table 1). It has, therefore, been suggested that the presence of maternal 
SSA alone represents a necessary but not sufficient condition for developing the 
disease. As a matter of fact, it would appear that foetal and environmental factors may 
also play a role. Neonatal lupus is a disease of the foetus or of the newborn that is 
caused by transplacental crossing of anti-Ro/SSA, anti-La/SSB maternal auto-
antibodies during pregnancy.5 It is an in-vivo passive acquisition model of auto-
immunity.With the exception of foetal heart block, neonatal manifestations usually 
disappear when the maternal antibodies clear, that is, at approximately the 6th to 8th 
month of life. Neonatal lupus is a rare syndrome. Many experts feel that the Brucato 
group in Italy has identified themost accurate incidence of NL in antibody-positive 
pregnancies. In their prospective study on the outcome of 100 pregnant women with 
anti-SSA/Ro antibodies, the incidence of CHB was 2%.14 In our opinion, the 
incidence of neutropenia in the newborns of ENA-positive mothers may be 
underestimated because a complete blood count is not usually performed in 
asymptomatic newborns.15 Given the rarity of the disease, little information 
concerning the management of children with neonatal lupus is available. Thus, both 
improving the approach to NL as well as long-term follow-up are mandatory. In fact, 
Martin, et al.16 suggested that children with neonatal lupus require continued follow-
up, especially before adolescence and if the mother herself has an autoimmune 
disease. Although there is no apparent increased risk of SLE, the development of 
some form of autoimmune disease (systemic or organ specific) in early childhood 
may be of concern. In conclusion, our case shows that special care should be taken to 
monitor CTD patients during and after pregnancy due to the potential occurrence of 
disease flare and/or evolution to a definite CTD. The rarity of NL as well as the 
difficulty in recruiting a large enough number of patients to carry out a reliable study 
account for the lack of standardised protocols. Careful study of the foetus and long-
term follow-up of babies are needed for several reasons, including reports of 
autoimmune diseases developing in patients who had NL as infants.  
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